HOME >> BIOLOGY >> NEWS
Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure

Positive Results of Phase I Study Presented At American College of Cardiology Conference

SEATTLE -- Immunex Corporation (NASDAQ:IMNX and Wyeth-Ayerst Laboratories announced today that they are beginning a Phase II/III clinical trial with ENBREL (etanercept) in chronic heart failure patients, one of the first large-scale studies undertaken to evaluate cytokine inhibition, an entirely new approach to studying chronic heart failure. This study will be based on positive results of a Phase I study presented today at the annual conference of the American College of Cardiology in New Orleans, LA.

Results of the double-blind, randomized, placebo-controlled multi-dose Phase I safety study in 47 heart failure patients demonstrated that ENBREL was well tolerated. The incidence of adverse events was similar in all treatment groups. The study was conducted by Dr. Douglas Mann and Dr. Guillermo Torre at Baylor College of Medicine, and Dr. Arthur M. Feldman at University of Pittsburgh Medical Center.

The 47 patients were New York Health Assessment (NYHA) class III-IV and were randomized to be treated for three months with twice weekly injections of either ENBREL at 5mg/m2, 12mg/m2 or placebo. At three months, measurements of clinical activity suggested consistent improvement for patients on ENBREL in NYHA classification, left ventricular ejection fraction, quality of life, and in a clinical composite score. In addition, there appeared to be a positive dose response in each of the categories above. Based on the results of the study, and additional clinical and preclinical data associating elevated TNF levels with chronic heart failure, the two companies have elected to proceed to a Phase II/III multicenter trial.

"We are pleased that the results of the multidose Phase I study supported moving into a Phase II/III multicenter trial," said Peggy Phillips, senior vic
'"/>

Contact: Pam Rabe
prabe@immunex.com
206-470-4131
Immunex Corporation
8-Mar-1999


Page: 1 2 3 4

Related biology news :

1. UWs new Cell Systems Initiative welcomes Immunex collaboration
2. Immunex Corporation and Genentech, Inc. join forces to develop TRAIL/Apo2L in cancer
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
5. Berlex Laboratories announces FDA approval of YASMIN (R), new oral contraceptive with unique progestin
6. FDA clears Berlex Laboratories Mirena (R), new form of long-acting contraception meets need for U.S. women
7. Advances in tumor angiogenesis Dendritic cells co-opted to the dark side
8. Advances in equine cloning may aid insight into human diseases
9. Advanced sensors, computing systems tracking sea animals worldwide
10. Lunch workshop at the American Association for the Advancement of Science (AAAS) Annual Meeting
11. Advance in developing biological strategies to produce hydrogen and sequester carbon dioxide

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology:
Cached News: